Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Sep;36(9):2051–2053. doi: 10.1128/aac.36.9.2051

Susceptibilities of members of the Bacteroides fragilis group to 11 antimicrobial agents.

R Horn 1, J Lavallée 1, H G Robson 1
PMCID: PMC192437  PMID: 1416899

Abstract

The susceptibilities of 200 clinical isolates of the Bacteroides fragilis group to 11 antimicrobial agents were determined by the broth microdilution method of the National Committee for Clinical Laboratory Standards. All isolates were susceptible to imipenem and ticarcillin-clavulanic acid. The rates of resistance to cefoxitin and clindamycin were low (4 and 6%, respectively), while those to ceftizoxime and cefotetan were higher (10.5 and 24%, respectively).

Full text

PDF
2053

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aldridge K. E., Sanders C. V. Antibiotic- and method-dependent variation in susceptibility testing results of Bacteroides fragilis group isolates. J Clin Microbiol. 1987 Dec;25(12):2317–2321. doi: 10.1128/jcm.25.12.2317-2321.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aldridge K. E., Wexler H. M., Sanders C. V., Finegold S. M. Comparison of in vitro antibiograms of Bacteroides fragilis group isolates: differences in resistance rates in two institutions because of differences in susceptibility testing methodology. Antimicrob Agents Chemother. 1990 Jan;34(1):179–181. doi: 10.1128/aac.34.1.179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Appelbaum P. C., Spangler S. K., Jacobs M. R. Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents. Antimicrob Agents Chemother. 1991 Jun;35(6):1214–1218. doi: 10.1128/aac.35.6.1214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Appleman M. D., Heseltine P. N., Cherubin C. E. Epidemiology, antimicrobial susceptibility, pathogenicity, and significance of Bacteroides fragilis group organisms isolated at Los Angeles County-University of Southern California Medical Center. Rev Infect Dis. 1991 Jan-Feb;13(1):12–18. doi: 10.1093/clinids/13.1.12. [DOI] [PubMed] [Google Scholar]
  5. Betriu C., Campos E., Cabronero C., Rodriguez-Avial C., Picazo J. J. Susceptibilities of species of the Bacteroides fragilis group to 10 antimicrobial agents. Antimicrob Agents Chemother. 1990 Apr;34(4):671–673. doi: 10.1128/aac.34.4.671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bourgault A. M., Harding G. K., Smith J. A., Horsman G. B., Marrie T. J., Lamothe F. Survey of anaerobic susceptibility patterns in Canada. Antimicrob Agents Chemother. 1986 Nov;30(5):798–801. doi: 10.1128/aac.30.5.798. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bourgault A. M., Lamothe F., Hoban D. J., Dalton M. T., Kibsey P. C., Harding G., Smith J. A., Low D. E., Gilbert H. Survey of Bacteroides fragilis group susceptibility patterns in Canada. Antimicrob Agents Chemother. 1992 Feb;36(2):343–347. doi: 10.1128/aac.36.2.343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Breuil J., Burnat C., Patey O., Dublanchet A. Survey of Bacteroides fragilis susceptibility patterns in France. J Antimicrob Chemother. 1989 Jul;24(1):69–75. doi: 10.1093/jac/24.1.69. [DOI] [PubMed] [Google Scholar]
  9. Brook I. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice. J Infect Dis. 1989 Oct;160(4):651–656. doi: 10.1093/infdis/160.4.651. [DOI] [PubMed] [Google Scholar]
  10. Cuchural G. J., Jr, Tally F. P., Jacobus N. V., Aldridge K., Cleary T., Finegold S. M., Hill G., Iannini P., O'Keefe J. P., Pierson C. Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation. Antimicrob Agents Chemother. 1988 May;32(5):717–722. doi: 10.1128/aac.32.5.717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cuchural G. J., Jr, Tally F. P., Jacobus N. V., Gorbach S. L., Aldridge K., Cleary T., Finegold S. M., Hill G., Iannini P., O'Keefe J. P. Antimicrobial susceptibilities of 1,292 isolates of the Bacteroides fragilis group in the United States: comparison of 1981 with 1982. Antimicrob Agents Chemother. 1984 Aug;26(2):145–148. doi: 10.1128/aac.26.2.145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Finegold S. M. Susceptibility testing of anaerobic bacteria. J Clin Microbiol. 1988 Jul;26(7):1253–1256. doi: 10.1128/jcm.26.7.1253-1256.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. García-Rodríguez J. E., García-Sánchez J. E. Evolution of antimicrobial susceptibility in isolates of the Bacteroides fragilis group in Spain. Rev Infect Dis. 1990 Jan-Feb;12 (Suppl 2):S142–S151. doi: 10.1093/clinids/12.supplement_2.s142. [DOI] [PubMed] [Google Scholar]
  14. Goldstein E. J., Citron D. M. Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group. J Clin Microbiol. 1988 Nov;26(11):2361–2366. doi: 10.1128/jcm.26.11.2361-2366.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hurlbut S., Cuchural G. J., Tally F. P. Imipenem resistance in Bacteroides distasonis mediated by a novel beta-lactamase. Antimicrob Agents Chemother. 1990 Jan;34(1):117–120. doi: 10.1128/aac.34.1.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lee K., Jang I. H., Kim Y. J., Chong Y. In vitro susceptibilities of the Bacteroides fragilis group to 14 antimicrobial agents in Korea. Antimicrob Agents Chemother. 1992 Jan;36(1):195–197. doi: 10.1128/aac.36.1.195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Peláez M. T., Cercenado E., Rodríguez-Créixems M., Bouza E. Resistance of anaerobic bacteria to antimicrobial agents. Rev Infect Dis. 1991 Jan-Feb;13(1):183–183. doi: 10.1093/clinids/12.5.183. [DOI] [PubMed] [Google Scholar]
  18. Scher K. S. Emergence of antibiotic resistant strains of Bacteroides fragilis. Surg Gynecol Obstet. 1988 Sep;167(3):175–179. [PubMed] [Google Scholar]
  19. Tally F. P., Cuchural G. J., Jr, Jacobus N. V., Gorbach S. L., Aldridge K., Cleary T., Finegold S. M., Hill G., Iannini P., O'Keefe J. P. Nationwide study of the susceptibility of the Bacteroides fragilis group in the United States. Antimicrob Agents Chemother. 1985 Nov;28(5):675–677. doi: 10.1128/aac.28.5.675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Wexler H. M., Finegold S. M. Antimicrobial resistance in Bacteroides. J Antimicrob Chemother. 1987 Feb;19(2):143–146. doi: 10.1093/jac/19.2.143. [DOI] [PubMed] [Google Scholar]
  21. Wexler H. M., Finegold S. M. In vitro activity of cefotetan compared with that of other antimicrobial agents against anaerobic bacteria. Antimicrob Agents Chemother. 1988 Apr;32(4):601–604. doi: 10.1128/aac.32.4.601. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES